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The need for radiotherapy personalization is now widely recognized, however, it would
require considerations not only on the probability of control and survival of the tumor,
but also on the possible toxic effects, on the quality of the expected life and the
economic efficiency of the treatment. In this paper, we propose a simulation tool that
can be integrated into a decision support system that allows selection of the most
suitable irradiation regimen. We used a macroscale mathematical model, which includes
active and necrotic tumor dynamics and the role of oxygenation to simulate the effects
of different hypo-/hyper-fractional regimens using retrospective data of seven virtual
patients from as many cervical cancer patients used for its training in a previous study.
The results confirmed the heterogeneous response across the patients as a function
of treatment regimen and suggested the tumor growth rate as a main factor in the
final tumor regression. In addition to the maximum regression, another criterion was
suggested to select the most suitable regimen (minimum number of fractions to achieve
a regression of 80%) minimizing the toxicity and maximizing the cost-effectiveness
ratio. Despite the lack of direct validation, the simulation results are in agreement with
the literature findings that suggest the need for hypo-fractionated regimens in case of
aggressive tumor phenotypes. Finally, the paper suggests a possible exploitation of the
model within a tool to support clinical decisions.
Keywords: radiotherapy, cervical cancer, hypofractionation, mathematical model, simulation, oxygenation
INTRODUCTION
According to the World Health Organization (WHO), cancer is the second leading cause of
mortality, and has been responsible for one in six deaths in 2015 worldwide. This is a major
burden in both developed and developing countries, with around 14 million new cases in 2012
and an increase of 70% for the next 20 years (Soerjomataram et al., 2012). There are two main
research paths available to address this problem. The first is to develop new treatment options by
investigating the mechanisms underlying the evolution of the tumor. The second is to optimize
and personalize treatments in clinical practice (e.g., drugs, surgery, and irradiation) to address the
heterogeneous response of the tumor to the therapy. Among treatment options, radiotherapy is the
most applied because it can be used it can be used either to reduce the extent of the tumor before
proceeding with surgery (Contin et al., 2014) or to irradiate the resection margins post-surgery
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(McGale et al., 2014). It can be also used as a palliative
therapy (Chow et al., 2007) and as an elective treatment alone
or concomitantly with adjuvant chemotherapy (Haddad et al.,
2013; Goldstein and Kastan, 2015). External Beam Radiation
Therapy (EBRT) is usually delivered to the patients by means
of multiple fractions characterized by the nominal dose that
must be conveyed to the region of interest including visible
tumor and micro-lesions (Burnet et al., 2004). Conventional
treatment consists of 1.8–2 Gy fractions delivered 5 days a week,
a therapeutic regimen established in early radiobiological studies
to maximize the curative effect while reducing toxicity (Colombo
et al., 2012).
Recently, the identification of patient-specific genomics and
radiomics (omics) biomarkers has suggested the possibility of
exploiting altered regimens (Ahmed et al., 2014). An accurate
and personalized approach to EBRT planning would require at
least two steps: (1) definition of the most suitable fractionation
program, including the nominal dose value per fraction, based
on patient-specific characteristics; (2) accurate delivery of the
nominal dose taking into account the anatomical-pathological
changes between fractions and intra-fraction organ movement
(Seregni et al., 2012). Regarding dose delivery, irradiation is
usually carefully planned by optimizing the beam entry and
activation strategies to administer the tumor with the prescribed
amount of dose while sparing the organ at risks (OAR). The dose
profile can be adjusted according to slow morphological changes
(inter-fraction) using a plan-of-the-day approach (Heijkoop
et al., 2014; Jones et al., 2015; Sharfo et al., 2016) while faster
dynamics (e.g., respiration) can be addressed by means of time
resolved images (Keall et al., 2006; Schaerer et al., 2012; Paganelli
et al., 2015). In other words, the level of treatment personalization
in dose delivery management can be quite impressive. On
the contrary, once the staging of the tumor has been defined
and radiotherapy or radiochemotherapy is selected accordingly,
the amount of irradiation dose to be administered during the
fractionated treatment often derives from the general guidelines
and the structure protocol (Colombo et al., 2012; Prokopiou et al.,
2015).
In the light of this clinical context, mathematical models
of tumor evolution and response to treatment could play
an important role allowing the customization of radiotherapy
simulating different irradiation protocols and thus supporting
the selection of the most effective (Stamatakos and Dionysiou,
2009). Mathematical models can range from statistical methods
to calculate the tumor control probability (TCP) and normal
tissue complication probability (NTCP) (Thames et al., 1983;
Lyman, 1985) to multiscale 3D models of cellular and subcellular
mechanisms that regulate tumor dynamics (Bellomo et al.,
2004; Stamatakos and Dionysiou, 2009; Boondirek et al., 2010).
Radiobiological models that evaluate the effects of radiotherapy
are routinely used in clinical practice. The best known is the
Linear Quadratic (LQ) model, which expresses the surviving
fraction of a cell population as a function of the irradiated dose
and tumor-/patient- specific radiosensitivity parameters. The LQ
model is also the starting point of the biological effective dose
(BED) computation, a measure that describes the biological
effect of radiation according to the specific treatment schedule
(Fowler, 1989, 2014). However, it is known that models failing to
incorporate tumor repopulation are not suitable for describing
the overall tumor evolution (Stocks et al., 2014). The model
complexity increases even further if specific aspects are taken into
account (for example cancer metabolism deregulation, genomic
factors) (Ghaffari et al., 2015; Oberhardt and Gianchandani,
2015). To properly address the problem of training and validation
for a complex model, it is necessary to collect morphological and
functional data. Therefore, despite the greater realism and detail
of the 3D multiscale models, simpler macroscale models focusing
on the scalar evolution of the tumor volume can be considered
(Hogea et al., 2008; Huang et al., 2010; Cornelis et al., 2013).
In previous studies, we presented different macroscale models
of tumor growth and response to radiotherapy, trained and
tested on both animal and clinical data (Belfatto et al., 2015,
2016a,b, 2017). In this work, we aimed at simulating the effects
of hyper- and hypo-fractionation schemes together with the
conventional schedule using the most complete of the proposed
model formulations (Belfatto et al., 2017). The adopted model,
including active and necrotic tumor cells and oxygenation
dynamics, had already been trained on the volume data of seven
patients, diagnosed with cervical cancer, who were treated using
the standard 1.8G/28-fraction EBRT regimen and monitored
using 3D-Doppler images. The simulated treatments, with the
same overall BED, were evaluated in terms of final tumor
regression. Further possible criteria for selecting the optimal
regimen have been identified.
MATERIALS AND METHODS
Model Definition, Training, and Validation
The equations regulating the evolution of active and necrotic
portions were extensively described in our previous work (Huang
et al., 2010). Hereafter, we summarize the overall model structure
briefly. The tumor volume is considered completely active and
growing before the treatment start (t0), while the irradiation
causes the decrease of the active tumor (Va) and the occurrence
of necrosis. The active volume grows spontaneously according
to the Gompertz (1825) model featuring two main parameters,
the growth rate (ρ) and the carrying capacity (k). Since the latter
describes the maximum amount of viable tumor sustainable by
the tissue, we assumed it to be reduced due the vasculature
damage following irradiation [k(t + 1) = k(t).SFv], given that the
carrying capacity before treatment is
∧
k. The surviving fraction of
the vasculature (SFv) and the one of the active tumor (SFt) are
assessed by means of the LQ formula (Fowler, 1989):
SF = e−αγd
(
1+ d
α/β
)
(1)
where α (Gy−1) is the radiosensitivity and α/β (Gy) is 10 and 3
for the tumor and vasculature, respectively. We considered an
additional coefficient γ accounting for the multiple cell killing
required to impair the vascular efficiency, therefore γ = 1 for the
tumor while γ is positive and lower than 1 for the vasculature. The
radiosensitivity depends on the average oxygen partial pressure
(PO2) within the tumor volume as widely recognized in the
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literature (Deschner and Gray, 1959; Fyles et al., 1998; Karlsson,
2004). We defined a linear relation between the two variables as:
α (t) = αmin + PO2 (t)100 · (αmax − αmin) (2)
where αmin = 0.001 Gy−1 and αmax = 0.3 Gy−1 in order to bound
the surviving fraction as 0.5 < SFt < 1 considering a standard
dose per fraction (1.8 Gy) and the selected α/β ratio (10 Gy). The
oxygen pressure is determined by the efficiency of the vasculature
and the amount of active cells consuming oxygen, therefore we
linked PO2 to both? (index of the environment status) and Va as
follows:
PO2 (t) = k (t)− Va (t)k (t) 100 (3)
Finally, the necrotic volume was simply reabsorbed, starting from
the corresponding irradiation day (ti), according to an inverse
exponential law defined by the half-time of dead cell clearance
(T1/2). The overall discrete equation system, considering a
N-fraction treatment, is therefore defined as:[
|a (t) + ρlogVVa(t+1)=
(
k (t)
Va (t)
)
Va (t)
]
· SFt (4)
Vn (t + 1) = Va (t) (1− SFt)+
N∑
i=1
Vn,ie
−log(2) t−tiT1/2 (5)
Vt (t + 1) = Va (t + 1)+ Vn (t + 1) (6)
The interplay among all the above mentioned variables is
graphically described in Figure 1, along with an example of
possible tumor evolution through time during the treatment
administration. The system featured four free parameters, namely
ρ,
∧
k, T1/2, and γ, while all other quantities were set according
to literature values as described in the text where they were
first introduced. Free parameters underwent patient-specific
optimization by means of a custom Montecarlo algorithm
implemented in MATLAB R© (The MathWorks, Inc., Natick, MA,
United States). The growth rate was searched in the interval
0.01< ρ< 0.2, the initial carrying capacity
∧
k was allowed to span
between 1 and 3 times the initial tumor volume (100 <
∧
k < 300),
while the dead cells clearance time (T1/2) was bounded between
2 and 30 days (Belfatto et al., 2017). Finally, γ, determining SFv,
was allowed to range in the [0 .. 1] interval. This was set to limit
the lethal effects of irradiation to the vasculature according to
the rationale of radiotherapy that healthy cells are less sensitive
than the tumor ones. The model was optimized according to the
methodology described in Belfatto et al. (2017) using the tumor
volume evolution (Vt) of seven woman (age range: 41–81 years),
listed from A to G, affected by uterine cervical cancer. Details of
FIGURE 1 | Model at glance. Upper panel: example of tumor evolution through time. Lower panel: active volume, necrotic volume, irradiation, and oxygenation
interplay diagram.
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the estimated parameters are depicted in Table 1. 3D-Doppler
indexes of vascularization and flow, namely the vascularization
index (VI), the Flow Index (FI and the Vascularization-Flow
Index (VFI), were exploited to validate the oxygenation dynamics
independently. Despite being related to the oxygen availability,
the aforementioned indexes do not correspond to the actual value
of oxygen pressure in the tumor. Therefore, the correlation values
between each of VI, FI, VFI and the model-based oxygenation
values (PO2) were considered as a measure of the model ability
to mimic the interplay among volume (active and necrotic) and
environmental condition dynamics.
The patients were scheduled for chemo-radiation exclusive
therapy because of histologically proven advanced cervical
cancer according to International Federation of Gynecology
and Obstetrics (FIGO) staging (1 IIA, 2 IIB, 3 IIB N+,
and 1 IVA) from September 2014 to July 2015. The study
was part of one current research program on image-guided
radiotherapy for gynecological cancer reported to and approved
by multidisciplinary gynecological oncology board (Institutional
Ethics Committee: notification no. 86/11) of the European
Institute of Oncology (Milan, Italy). All patients gave written
informed consent for the treatment and for the use of the
anonymized data for research or educational purpose. The data
were collected in European Institute of Oncology institutional
database (RTP R036-000-BRACHI-GINE).
Treatment Simulation Protocol
Theoretically, there are no limits to the treatment schemes
that could be simulated by means of the model described.
However, some considerations are in order: (a) the amount
of dose delivered should suffice to treat the tumor or at least
significantly reduce its volume; (b) the healthy tissue toxicity
should be avoided; and (c) the model was trained and tested on
1.8 Gy × 28 fractions protocols only. We decided to leave the
standard irradiation schedule of 5 days per week unvaried while
analyzing the effect of changes in the dose profile.
In order to provide a reasonable amount of irradiation to the
patient, we imposed BED ∼= 60 Gy as this is about the BED
value for a 1.8 Gy/fraction treatment delivered in 28 sessions
considering α/β = 10 Gy. Although setting α/β = 10 Gy is in
agreement with both literature and clinical practice (Dale, 1996),
the ratio is actually dependent on the tissue type, dose amount
and even oxygenation (Williams et al., 1985; Fowler, 2001; Lee
et al., 2014). Therefore, the simulations should be performed
TABLE 1 | Estimated model parameters, namely ρ, T1/2,
∧
k, and, γ computed in
the Montecarlo optimization procedure.
Patient ρ (rate) T1/2 (days)
∧
k (%) γ (rate)
A 0.17 14 220 0.9
B 0.07 28 150 0.7
C 0.08 4 125 0.7
D 0.02 22 300 0.9
E 0.02 30 140 0.8
F 0.10 30 120 0.6
G 0.10 30 120 0.7
acknowledging the limits of the model extrapolation abilities.
Two main types of treatments were defined: (1) hypo/hyper
fractionated schemes featuring a constant value of dose per
fraction; (2) non-constant schemes featuring dose gradients
(increasing/decreasing dose trends). According to the previous
consideration the dose boundaries were defined for the constant
dose treatment (0.5 Gy ≤ d/fraction ≤ 3 Gy) and for the
non-constant dose ones (0.5 Gy ≤ d/fraction ≤ 4.5 Gy, average
dose: 2.5 Gy) as shown in Figure 2.
In order to compute the BED in case of non-constant dose
administration the following formula was applied (Fowler, 2014):
BED =
n∑
i=1
(
1+ d
α
/
β
)
(7)
where i is the index that scans the n irradiation composing
the overall treatment. All the simulations were performed
considering a relative tumor volume evolution, in other words
the initial tumor volume was set equal to 100% at t = 0 (first
irradiation).
RESULTS
The aim of the treatment is to necrotize the tumor, therefore,
the overall final mass may be not as relevant as the residual
active portion since, eventually, the necrotic volume is going to
be washed out physiologically. As a matter of fact, an advantage of
using the proposed model is to be able to tell the two components
apart and to focus the analysis on the viable volume only.
Since the model was trained on the overall tumor volume only,
we started investigating whether analyzing the active volume
instead of the total volume implied the selection of a different
optimal treatment according to the criterion of the maximum
final volume reduction. The two criteria (total volume vs. active
volume reduction) resulted in agreement in all the cases except
for patient B (Table 1) where according to Vt the best treatment
was d = 1.8 Gy, while, considering Va, d = 2 Gy was to be selected.
It has to be remarked that for patient B the two treatments
(d = 1.8 Gy and d = 2 Gy) provided comparable performances
(final volume variation ∼= 0.5) as shown in Figure 3, and
that both are considered standard regimens (strd) in clinical
practice. Given the abovementioned considerations, the result
presentation and the following discussion will focus on the active
volume only. Among the seven patients, three benefited more
from hypofractionated treatment, two showed a larger regression
by means of the standard schedule and the remaining two
performed better under hypofractionated regimen (see Table 2).
Different correlation values [c(d,V)] between dose delivered
and final volume size were found, which reflected the value
of the growth rate. The hypo group [patients A, F, and G,
c(d,Va(te))<−0.75] featured ρ≥ 0.1, for the strd group [patients
B and C, c(d,Va(te)) ∼= −0.5] 0.07 < ρ < 0.08 and for the hyper
group ρ < 0.05 [patients D and E, c(d,Va(te)) > 0.97]. In other
words, the growth rate (ρ) appeared to be a discriminating factor
in the treatment selection. Four patients (B, D, E, and F) reached
80% active volume reduction [Va(te) < 20] at least with one
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FIGURE 2 | Summary of the simulation scheme.
FIGURE 3 | Example of active volume evolution. Viable tumor regression according to different constant-dose fractionation schemes for Patient B.
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TABLE 2 | The final volume tumor volume is shown for the constant-dose treatments according to the patient and the dose per fraction administered (1 Gy < d < 3 Gy)
considering the overall tumor [V t (te), upper panel] and the active portion [Va(te), lower panel], respectively.
Patient d = 1 d = 1.5 d = 1.8 d = 2 d = 2.5 d = 3 c[(d,Vt(te)] Best treatment
Final overall volume – Vt (te) [%]
A 73.65 48.22 40.27 36.89 32.22 31.04 −0.842 d = 3 hypo
B 20.95 10.80 9.67 10.15 12.27 18.01 −0.495 d = 1.8 strd
C 45.12 29.37 26.53 26.24 27.71 31.35 −0.653 d = 2 strd
D 1.00 1.66 2.42 3.10 5.18 8.32 0.984 d = 1 hyper
E 5.33 9.19 12.67 15.66 22.93 31.71 0.990 d = 1 hyper
F 51.50 28.15 22.83 22.44 23.30 30.36 −0.696 d = 2.5 hypo
G 63.68 47.39 43.16 42.36 42.85 47.61 −0.725 d = 2.5 hypo
Patient d = 1 d = 1.5 d = 1.8 d = 2 d = 2.5 d = 3 c[d,Va(te)] Best treatment
Final active volume – Va(te) [%]
A 73.28 47.84 39.96 36.49 31.80 30.44 −0.883 d = 3 hypo
B 19.54 8.56 7.34 7.07 8.18 10.48 −0.515 d = 2 strd
C 44.52 28.09 25.29 24.54 26.00 29.41 −0.571 d = 2 strd
D 0.88 1.48 2.24 2.87 4.87 7.17 0.974 d = 1 hyper
E 4.12 7.21 10.58 13.07 20.06 26.84 0.989 d = 1 hyper
F 49.44 22.32 16.34 13.72 12.18 13.07 −0.794 d = 2.5 hypo
G 62.82 45.31 40.64 38.89 38.38 40.44 −0.754 d = 2.5 hypo
Only three patients (B, D, and E) reached the 80% reduction (final volume <20%), in bold the lowest final volume. The last two columns of both tables show the correlation
between the dose per fraction and the tumor at the end of irradiation (te) and the best treatment according to the lowest final volume criterion. Considering either the
active or total volume the optimal treatment changes only for patient B as underlined.
fractionation scheme. It has to be pointed out that all of them
obtained such reduction with the standard treatment even if in
some cases other fractionation schemes allowed even a larger
regression. Therefore, in case of Va(te) < 20, we introduced a
secondary treatment ranking tacking into consideration an early
radiotherapy interruption once the 80% reduction is achieved,
checking the BED delivered until then. This approach can be
used in case the main goal of EBRT is to reach a suitable
tumor reduction before administering other treatments (e.g.,
brachytherapy, chemotherapy, etc.). It allows a reduction in the
dose administration and, reasonably, a decrease in the NTCP
including, for instance, toxicity and acute reactions. The results
of such analysis are shown in Table 3, where the new BED
is provided and the best treatment option, according to the
TABLE 3 | BED of the partial treatment.
BED (Gy)
Patient d = 1 d = 1.5 d = 1.8 d = 2 d = 2.5 d = 3
A − − − − − −
B 58.3 27.6 23.4 24.0 25.0 27.3
C − − − − − −
D 11.0 10.3 12.7 9.6 12.5 11.7
E 24.2 25.9 29.7 31.2 − −
F − − 50.9 48.0 43.7 42.9
G − − − − − −
For each of the four patients able to reach the 80% tumor reduction (B, D, E,
and F) the BED is computed considering an early treatment stop as soon as the
Va(te) < 20 threshold is reached.
BED minimizing criterion, is highlighted. The results of the
non-constant dose administration are depicted in Figure 4, where
the simulation of the active tumor evolution is shown for each
patient according to the decreasing (upper panel) and increasing
(lower panel) trends, respectively. Neither of the treatment did
systematically outperform the other, as in the constant-dose
fractionation the optimal strategy was to be selected individually
for each patient. Despite the fact that both fractionation involved
exactly the same dose administration (in the reverse order) the
final volumes of the same patient varied on average of about 10%
considering the initial volume
(∣∣∣∣ ∧Va (te)− ∨Va (te)∣∣∣∣) and over
40% with respect to the final volume itself

∣∣∣∣ ∧Va(te)− ∨Va(te)∣∣∣∣( ∧
Va(te)+
∨
Va(te)
)
/2
,
where
∧
Va (te) and
∨
Va (te) are the final active volumes for the
increasing and decreasing treatment, respectively. The treatment
featured 0.5 Gy < d < 4.5 Gy and a 1d = 0.25 between
consecutive fractions.
Major Findings
The simulations performed in this study, using a model
trained on clinical patient data, highlight the potential of
exploiting mathematical modeling in radiotherapy planning. It is
possible to identify four main findings: (1) each virtual patient
reacts differently when administered with the same hypo/hyper
fractionated regimen; (2) the maximum tumor reduction was
obtained with different fractionation schemes for each of the
seven patients; (3) an early treatment stop for some patients
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could theoretically allow a reduction of BED administration,
while ensuring a greater reduction (80%) of the tumor volume;
(4) reversal of the dose administration order in a non-constant
dose schedule, causes an average variation of 40% in the final
active volume.
First of all, we noticed that the same treatment can behave very
differently depending on the patient characteristics, even if it was
expected, given that the data used for the training itself showed
large variability even in the final regression (20–90%) (Belfatto
et al., 2017). For example, the hyperfractionation (d = 1) leads to
a reduction of less than 30% for patient A and more than 99%
for patient D (see Table 2). Observing the model parameters, it
can be easily seen that these patients are those with the lowest
(patient D) and the largest growth rate (patient A), respectively.
Therefore, it is perfectly reasonable that a longer treatment period
(hyper-fractionation) would result in a greater tumor progression
in A than D reducing the effectiveness of irradiation in the
second.
The opposite analysis, which studies the best treatment option
for each patient, is probably the most interesting because of its
clear potential impact in clinical practice: the personalization of
treatment. The study showed that the same patient administered
with the same BED by a different fractionation regime could
result in a variation of more than 40% in the reduction of
the final volume, e.g., patient A: final active volume equal
to 73% if d = 1 and 30% if d = 3 (see Table 2). We
hypothesized, for the purpose of this analysis, that the best
treatment option for each patient was the one that provides
the widest regression (Lee et al., 2014). The tumor growth rate
plays a key role, allowing discrimination among patients who
could benefit most from hypo-, hyper- or standard fractionation,
according to the literature (Fowler, 2001). A previous study,
which investigated the possibility of selecting altered regimens
(hypo/hyper fractionation) based on patient-specific models,
suggested that the carrying capacity was the most relevant factor
(Prokopiou et al., 2015). The authors introduced a proliferation
saturation index (PSI) that describes the tumor volume compared
to the carrying capacity, assuming the higher the ratio the
lower the proliferation of cells, since the tumor is close to
its saturation. PSI showed high inverse correlation with the
radiotherapy response, in agreement with the fact that low
proliferation implies reduced radiosensitivity and also seemed
to identify the optimal radiation regimen. In our case, patients
A and D had a PSI of 0.45 and 0.33, respectively. Those were
actually the smallest PSI values in the dataset, however, the
two patients showed opposite behavior as described above. This
apparent inconsistency can have more explanations. The curve
used in Prokopiou et al. (2015) to fit the data was a Logistic
function instead of a Gompertzian as in the present study, so
even if the parameters represent the same biological characteristic
they have different values. The authors tested the model on a
different cancer type (non-small cell lung cancer). They did not
include the dynamics of dead-cell clearance and considered a
constant carrying capacity. In particular, they acknowledged that
the constant carrying capacity is a limitation of their work, which
we have overcome in the present study (Prokopiou et al., 2015).
The selection of the optimal fractionation scheme could also be
performed using different criteria such as the minimum BED to
be administered to obtain a predefined regression (80%). This
approach can be used only for the treatments that actually reach
the selected threshold of tumor reduction. The analysis showed
that in some cases the BED could be limited to 1/6 of its standard
value (60 Gy) considering a 1.8 Gy × 28-fractions treatment,
implying a reduced irradiation of the healthy tissue surrounding
the gross tumor volume lowering the NTCP. The minimum-BED
criterion can be exploited especially in case of multi-modality
treatments, when the EBRT objective is not to completely sterilize
the tumor but to reduce it sufficiently to proceed with the
following treatment step (e.g., either brachytherapy or surgery).
It is important to note that this would also reduce the treatment
cost per patient, which is a critical aspect in modern medicine,
while ensuring a greater tumor regression.
In conclusion, according to the model, not only the amount
of dose per fraction but also the order used to administer it is
relevant to the endpoint (final active volume). Patients A (largest
ρ) and patient D (lowest ρ) still exhibit opposite behaviors. Faster
growth requires a very aggressive treatment in the initial stages
to limit its effect while, in the case of slower growth, higher doses
are required when the vasculature impairments has reduced the
tumor oxygenation and, consequently, its radiosensitivity.
Limitations
This work presents some limitations that can be summarized as:
(1) reduced number of virtual patients; (2) model training limited
to the overall tumor volume only and no separate validation
for the viable portion; (3) model training based on a standard
fractionation regimen only (1.8 Gy× 28 fractions); and (4) lack of
an explicit definition of the irradiation effects on healthy tissues.
The number of virtual patients was limited by the number
of actual patients on whom the model had been trained in
the previous study. We are aware that the reduced number of
parameter sets does not allow meaningful statistics. However, the
point of this study was to highlight the need for personalization in
radiotherapy fractionated regimens and propose a mathematical
framework to support the best regimen selection. The wide
variability in the results of simulations of the same treatment on
different patients, as well as of the same patient administered with
different treatments, supports our initial hypothesis and makes
the results of this work promising while preliminary. Future
studies increasing the patient cohort are in order to confirm them.
Although model training was performed minimizing the error
between the measured volume and the sum of predicted active
and necrotic volumes, the validation was performed by means
of oxygen-related indexes derived from the 3D-Doppler images
(Huang et al., 2010). A high correlation was found between the
model prediction of tumor oxygenation, which is the product of
a complex network of mutual interconnections also on the active
tumor and of the indices mentioned above in some patients.
Therefore, the validation of predicted oxygenation is an indirect
proof of the accurate estimate of the viable portion dynamics.
In this work, we have also showed that the selection of the best
treatment, according to the maximum regression criterion, would
not have differed considering the total volume of the tumor
instead of the viable portion only.
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FIGURE 4 | Non-constant dose administration – simulation results. The viable tumor regression is shown for each patient simulating a decreasing dose
administration trend (left panel) and an increasing one (right panel).
FIGURE 5 | Model supported treatment planning.
The generalization of a model trained on a specific dose
schedule to other fractionation schemes is not straightforward.
We are aware that some radiobiological parameters may be
dependent on the dose (Williams et al., 1985; Nahum et al., 2003;
Astrahan, 2008) and that this can limit the prediction reliability.
However, we have addressed this issue by working within a
reasonable range of dose administration (0.5 Gy ≤ d ≤ 4.5 Gy).
The fact that the treatment is administered in a one-size-fits-all
solution, which is exactly the problem addressed in this work, has
prevented the observation of the effects due to different regimens.
In order to include them, a multi-center repository should be
used.
The toxicity of healthy tissue is a critical aspect of radiotherapy
that must be taken into account. In order to provide a
realistic scenario for each of the presented simulations, the
corresponding dose profile should have been generated, the
dose delivered to the organs at risk assessed and its effects
modeled. A correlation between this and the long terms
effects would finally have allowed a new treatment selection
criterion. This assessment was beyond the scope of our analysis
since it largely depends on the irradiation modalities (e.g.,
number of beams, use of IMRT, etc.). Therefore, we focused
only on providing realistic treatments, forcing the BED to be
∼=60 in addition to the limitation of the maximum dose per
fraction.
Final Remarks
Although this is a simulated study, the proposed model was
trained on real patient data. In principle, this approach makes
it possible to predict the effects of any irradiation treatment on
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a generic patient, provided that the corresponding parameter
signature (ρ, T1/2,
∧
k, and γ) is identified. We hypothesize
that a model-supported treatment planning tool can be built
on the basis of the model presented (Figure 5) by providing
a personalized dose delivery regimen. In this scenario, the
real treatment can be updated thanks to the monitoring of
tumor response, which can guide the adjustment of model
parameters, and this in turn can determine a change in the
treatment strategy at run-time. In detail, while a new patient
enters the protocol, tumor staging and patient profile (e.g.,
age, pre-existing conditions, etc.) may determine the selection
of an appropriate group-specific model (block A) defined by
a specific set of parameters, which represent a consistent
patient population (tumor growth rate, radio-sensitivity, carrying
capacity). The support to select a tailored treatment is ensured
thanks to the simulation in bundle of different irradiation
protocols (block B) which can feature different dose profiles and
inter-fraction interruptions as well. They can be ranked according
to either the maximum regression by selecting the treatment
leading to min(Va(te)) or according to the minimum BED
criterion [min(BED(te))], depending on the specific treatment
requirements. For example, if the aim is to achieve a certain
tumor shrinkage in order to allow surgery, the fractionation
scheme leading to an adequate reduction while minimizing
the dose delivered to the patient (according to the model
predictions), should be promoted. After selecting the optimal
treatment regimen, in accordance with clinical expertize and
institutional guidelines, the patient begins the curative path.
During the radiation course, the tumor evolution is monitored
by means of the acquisition of morphologic/functional images.
The sensible data, extracted from images, can be used to better
tune the parameters of the group-specific model to cope with
the patient-specific response (block C). An example of model
refinements by means of a parameter adaptation approach
along the treatment administration is described in Belfatto
et al. (2016c). New simulations can be then performed and the
treatment strategy may be revised accordingly (back to block
A, with updated parameters). In principle, this approach could
exploit the potential of tumor modeling to allow the treatment
to be personalized more objectively and quantitatively than the
standard profile. Moreover, it can take advantage of data already
acquired for tumor monitoring and patient positioning. This
makes the model-based treatment support system interesting and
worthy of further investigation, mandatory for its translation into
clinics.
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